Cornerstone Advisory’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$232K Buy
443
+35
+9% +$17.9K 0.02% 256
2026
Q2
$203K Buy
+408
New +$181K 0.02% 268
2022
Q1
– Sell
-34
Closed -$7K – 775
2021
Q4
$7K Buy
+34
New +$6.61K ﹤0.01% 645

Other funds holding VRTX

Cornerstone Advisory's VRTX Position: Q3 2026 in Review

Cornerstone Advisory increased its Vertex Pharmaceuticals (VRTX) stake by 8.6% in Q3 2026, buying an estimated $17.9K and bringing the position to 443 shares worth $232K. The position accounts for 0.02% of the portfolio, ranked #256.

Cornerstone Advisory first reported a position in VRTX in Q4 2021 and has held it in 3 quarters since. 1,014 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Cornerstone Advisory held 443 shares of Vertex Pharmaceuticals worth $232K as of Q3 2026.
  • Cornerstone Advisory bought 35 Vertex Pharmaceuticals shares in Q3 2026, an estimated $17.9K.
  • Vertex Pharmaceuticals made up 0.02% of Cornerstone Advisory's portfolio in Q3 2026, its #256 holding.
  • Cornerstone Advisory first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 3 quarters since.
  • 1,014 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Cornerstone Advisory's 13F filing for Q3 2026, filed 6 Nov 2026.